Упрощенная HTML-версия
62
4
-
L
<
< <
D(9+$+'&$%+ &% $6/'7 (-%+*+3/8%/-D+9-&2 %/8(3++ C&):-76 &$-&9-&2
*80337 $%8(%+=+5+8&9()+ 9 3 3&4*80337 (3&)01(HI+6 '&-&.&'3&-/-%-0H,
4906- + %8/6.&'3&-/-%-0H %/8(3+H $&&%9/%$%9/--&)
.
6/'( (-%+*+3/8%/-D+9-&2 %/8(3++ 9.)H1()(: '&-&%/8(3+H +-*+C+%&8&'
(-*+&%/-D+--38/98(I(HI/*&
=/8'/-%(
(+
)
– 3&4*8033(
1;
.&'C+-+8&9(--0H %/8(3+H +
+ 4+08/%+.&' ( ) – 3&4*8033( 2;
.&'C+-+8&9(--0H %/8(3+H +
,
+
1
-(48/-&C)&.(%&8&' ( ) –
3&4*8033( 3.
.(1/$%9/ $8/4$%9 .&'C+-+8&9(--&2 %/8(3++ +$3&):D&9()+:
)+3&=+):-72 +
F-()(38+) 9 6+'+1/$.&2 =&8'/ F-()(38+)( '()/(%(
(8/-+%/., Merck Sharp & Dohme B.V.),
*+48&6)&8%+(D+4 (*+3&%+(D+4,
hinoin)
, $/)/.%+9-72 )+3&=+):-72
'/%&38&)&) 9 6+'+1/$.&2 =&8'/
'/%&38&)&)( %(8%8(%( (F*+)&., Egis Pharmaceuticals Ltd.). 7C&8 )/.(8$%9/--76
$8/4$%9 + +6 38/3(8(%&9 9 8('.(6 -($%&,I/*& +$$)/4&9(-+, &$-&979()+ -( +6
%+3+1-&$%+, F==/.%+9-&$%+ + +D01/--&$%+.
4.1. "'$'-(& !+ A!/! (/'& ' ! &%& %+$'+ %/?!$%* ' !$(@ 0%"%& ' / !
9%"#$3A, $! C%$( 4%$% %40%$($ $%@ !$ '?'0(/ ($.'*$%@ (/!0''
&)+1/$%9/--(, 6(8(.%/8+$%+.( +-4/.$&9, 6(8(.%/8+D0HI+6 $&$%&,-+/
&8*(-&9 + %.(-/2 3&)&$%+ 8%( 0 C&):-76 $ .(84+&9($.0),8-&2 3(%&)&*+/2,
3&)01(HI+6 '&-&%/8(3+H, 38/4$%(9)/-( 9 %(C)+5/ 13.